Similar companies
Income Statement (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Revenue | 6.7M | 4.3% |
| Gross Profit | 3.5M | 18.3% |
| Cost of Revenue | 3.3M | 6.6% |
| Operating expense | 11M | 1.1% |
| Net Income | -6.9M | 121.1% |
| EBITDA | -4.3M | 48.7% |
Balance Sheet (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Total Assets | 76M | 3.1% |
| Total Liabilities | 31M | 1.4% |
| Total Equity | 45M | 5.8% |
| Shares Outstanding | 3.4M | 27.7% |
Cash Flow (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Cash from operations | -3.5M | 26.2% |
| Cash from investing | 2M | 114.1% |
| Cash from financing | 1.5M | 86.5% |
EPS
Financial Highlights for Bionano Genomics in Q2 '25
Bionano Genomics reported a revenue of 6.7M, which is a 4.3% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 3.5M, marking a 18.3% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 3.3M, a 6.6% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 11M, showing a -1.1% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -6.9M, showing a -121.1% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -4.3M, showing a 48.7% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Bionano Genomics faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. An increase in the cost of revenue, higher than the revenue growth, suggests potential margin pressures.
